论文部分内容阅读
帕金森病的治疗因运动症状的波动而复杂化,主要目的应稳定左旋多巴血浓度。PO40-7592系一种选择性周围和中枢儿茶酚-O-甲基转移酶(catechol—O—methyltransferase,COMT)抑制剂,可以增加左旋多巴的半衰期和生物利用度,本文报告单剂量口服PO40-7592加美多巴(左旋多巴/苄丝肼)对帕金森病人的临床疗效。 11例有“开—关”(On—Off)波动体征的帕金森病人,行双盲安慰剂对照试验;男4例,女7例,平均年龄67岁,平均病程12.5年,平均左旋多巴治疗时间11.6年。所有病人随机短时接受美多巴
The treatment of Parkinson’s disease is complicated by the fluctuation of exercise symptoms, and the main purpose should be to stabilize the blood concentration of levodopa. PO40-7592 is a selective peripheral and central catechol-O-methyltransferase (COMT) inhibitor that increases the half-life and bioavailability of levodopa. This article reports that single-dose oral Clinical efficacy of PO40-7592 plus dopa (levodopa / benserazide) in Parkinson’s disease. Eleven patients with Parkinson’s disease with on-off sign were double-blind placebo-controlled trial. There were 4 males and 7 females, with an average age of 67 years and an average duration of 12.5 years. Mean levodopa Treatment time 11.6 years. All patients received metropodan short-term random